Peer Review reports
From: Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution
| Original Submission | ||
|---|---|---|
| 16 Apr 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 31 Aug 2022 | Reviewed | Reviewer Report |
| 22 Oct 2022 | Reviewed | Reviewer Report - Hideki Maeda |
| 20 Nov 2022 | Author responded | Author comments - Ning Li |
| Resubmission - Version 3 | ||
| 20 Nov 2022 | Submitted | Manuscript version 3 |
| 23 Nov 2022 | Author responded | Author comments - Ning Li |
| Resubmission - Version 4 | ||
| 23 Nov 2022 | Submitted | Manuscript version 4 |
| 2 Dec 2022 | Author responded | Author comments - Ning Li |
| Resubmission - Version 5 | ||
| 2 Dec 2022 | Submitted | Manuscript version 5 |
| 7 Dec 2022 | Reviewed | Reviewer Report - Hideki Maeda |
| 16 Jan 2023 | Reviewed | Reviewer Report |
| 18 Jan 2023 | Author responded | Author comments - Ning Li |
| Resubmission - Version 6 | ||
| 18 Jan 2023 | Submitted | Manuscript version 6 |
| Publishing | ||
| 13 Mar 2023 | Editorially accepted | |
| 30 Mar 2023 | Article published | 10.1186/s12877-023-03886-2 |
You can find further information about peer review here.